Literature DB >> 25538683

Obesity-induced inflammation and insulin resistance.

Tsuguhito Ota1.   

Abstract

Entities:  

Keywords:  adipose tissue; bariatric surgery; inflammation; innate immunity; insulin resistance; macrophage; obesity; pattern-recognition receptor

Year:  2014        PMID: 25538683      PMCID: PMC4255620          DOI: 10.3389/fendo.2014.00204

Source DB:  PubMed          Journal:  Front Endocrinol (Lausanne)        ISSN: 1664-2392            Impact factor:   5.555


× No keyword cloud information.
Immune response and metabolic regulation are highly integrated and this interface maintains a central homeostatic system, dysfunction of which can cause obesity-associated metabolic disorder such as type 2 diabetes, fatty liver disease, and cardiovascular disease. Insulin resistance is an underlying basis for the pathogenesis of these metabolic diseases. Overnutrition or obesity activates the innate immune system with subsequent recruitment of immune cells such as macrophages and T cells, which contributes to the development of insulin resistance. In particular, a significant advance in our understanding of obesity-associated inflammation and insulin resistance has been recognition of the critical role of adipose tissue macrophages (ATMs). ATMs are a prominent source of proinflammatory cytokines, such as TNF-α and IL-6, that can block insulin action in adipose tissue, skeletal muscle, and liver autocrine/paracrine signaling and cause systemic insulin resistance via endocrine signaling, providing a potential link between inflammation and insulin resistance. All articles in this topic highlight the interconnection between obesity, inflammation, and insulin resistance in all its diversity to the mechanisms of obesity-induced inflammation and role of immune system in the pathogenesis of insulin resistance and diabetes. These articles give some insight into unanswered questions in relation to this topic. First, the relationship between nutrient sensing systems and the interface of metabolic and inflammatory responses is complex. Pattern-recognition receptors (PRRs) such as Toll-like receptors (TLR) and the receptor for advanced glycation end-products (RAGE) are activated in response to dietary nutrients and changes of gut microbiota as described in the review articles by Tanti et al. and Yamamoto et al. (1, 2). The activation of PRRs plays a crucial role as a trigger of this metabolic inflammation. Retinoic acid-related orphan receptors RORα and RORγ, also provide an important link between the circadian clock machinery and its regulation of metabolic genes (3). Two studies by Moustaid-Moussa et al. show a potential role of the renin angiotensin system in the development of insulin resistance and diabetes by using gain and loss of function in mice (4, 5). Second, it is not clear which cell recruits and activates or which tissue inflammation initially occurs upon obesity, which then causes systemic inflammation and subsequent development of insulin resistance. McArdle et al. and Tateya et al. describe how obesity causes alteration of the immune cells, in which TH1 cells, B cells, neutrophils, or mast cells induce M1 activation and polarization of macrophages by the elevated secretion of TNFα and IFNγ (6, 7). In addition to proinflammatory cytokines and adipokines, more metabolic regulators including fibroblast growth factor (FGF) family such as FGF 21 and FGF19 and bioactive lipids, sphingolipids can contribute to the development of systemic inflammation and subsequent development of insulin resistance (8, 9). Interestingly, these novel adipokines can be dramatically changed after bariatric surgery and these changes contribute to improvement of obesity-associated inflammation, insulin resistance, and glucose homeostasis (10). Overall, all the original articles and review articles covering this topic in all its diversity to contribute somewhat to clarify unanswered questions on the mechanisms of obesity-induced inflammation and insulin resistance.

Conflict of Interest Statement

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
  10 in total

1.  Mechanisms of obesity-induced inflammation and insulin resistance: insights into the emerging role of nutritional strategies.

Authors:  Maeve A McArdle; Orla M Finucane; Ruth M Connaughton; Aoibheann M McMorrow; Helen M Roche
Journal:  Front Endocrinol (Lausanne)       Date:  2013-05-10       Impact factor: 5.555

2.  Retinoic acid-related orphan receptors α and γ: key regulators of lipid/glucose metabolism, inflammation, and insulin sensitivity.

Authors:  Anton M Jetten; Hong Soon Kang; Yukimasa Takeda
Journal:  Front Endocrinol (Lausanne)       Date:  2013-01-25       Impact factor: 5.555

3.  Implication of inflammatory signaling pathways in obesity-induced insulin resistance.

Authors:  Jean-François Tanti; Franck Ceppo; Jennifer Jager; Flavien Berthou
Journal:  Front Endocrinol (Lausanne)       Date:  2013-01-08       Impact factor: 5.555

4.  Angiotensinogen gene silencing reduces markers of lipid accumulation and inflammation in cultured adipocytes.

Authors:  Wenting X Carroll; Nishan S Kalupahana; Suzanne L Booker; Nalin Siriwardhana; Monique Lemieux; Arnold M Saxton; Naima Moustaid-Moussa
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-11       Impact factor: 5.555

5.  Transgenic mice overexpressing Renin exhibit glucose intolerance and diet-genotype interactions.

Authors:  Sarah J Fletcher; Nishan S Kalupahana; Morvarid Soltani-Bejnood; Jung Han Kim; Arnold M Saxton; David H Wasserman; Bart De Taeye; Brynn H Voy; Annie Quignard-Boulange; Naima Moustaid-Moussa
Journal:  Front Endocrinol (Lausanne)       Date:  2013-01-07       Impact factor: 5.555

6.  Effects of bariatric surgery on adipokine-induced inflammation and insulin resistance.

Authors:  Zeynep Goktas; Naima Moustaid-Moussa; Chwan-Li Shen; Mallory Boylan; Huanbiao Mo; Shu Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2013-06-10       Impact factor: 5.555

7.  Sphingolipid metabolism and obesity-induced inflammation.

Authors:  Se-Chan Kang; Bo-Rahm Kim; Su-Yeon Lee; Tae-Sik Park
Journal:  Front Endocrinol (Lausanne)       Date:  2013-06-04       Impact factor: 5.555

8.  RAGE-Mediated Inflammation, Type 2 Diabetes, and Diabetic Vascular Complication.

Authors:  Yasuhiko Yamamoto; Hiroshi Yamamoto
Journal:  Front Endocrinol (Lausanne)       Date:  2013-08-21       Impact factor: 5.555

9.  Clinical implications of adipocytokines and newly emerging metabolic factors with relation to insulin resistance and cardiovascular health.

Authors:  Sung Hee Choi; Eun Shil Hong; Soo Lim
Journal:  Front Endocrinol (Lausanne)       Date:  2013-08-21       Impact factor: 5.555

10.  Recent advances in obesity-induced inflammation and insulin resistance.

Authors:  Sanshiro Tateya; Francis Kim; Yoshikazu Tamori
Journal:  Front Endocrinol (Lausanne)       Date:  2013-08-08       Impact factor: 5.555

  10 in total
  8 in total

1.  Blocking gp130 signaling suppresses autotaxin expression in adipocytes and improves insulin sensitivity in diet-induced obesity.

Authors:  Shuhong Sun; Ran Wang; Jianwen Song; Ming Guan; Na Li; Xiaotian Zhang; Zhenwen Zhao; Junjie Zhang
Journal:  J Lipid Res       Date:  2017-09-05       Impact factor: 5.922

2.  Energy balance and macronutrient distribution in relation to C-reactive protein and HbA1c levels among patients with type 2 diabetes.

Authors:  Hiba Bawadi; Rami Katkhouda; Ahmad Al-Haifi; Reema Tayyem; Cosette Fakih Elkhoury; Zeina Jamal
Journal:  Food Nutr Res       Date:  2016-05-27       Impact factor: 3.894

3.  Increased expression of triggering receptor expressed on myeloid cells-1 in the population with obesity and insulin resistance.

Authors:  Saravanan Subramanian; Pradeep K Pallati; Vikrant Rai; Poonam Sharma; Devendra K Agrawal; Kalyana C Nandipati
Journal:  Obesity (Silver Spring)       Date:  2017-01-23       Impact factor: 5.002

4.  Impact of carbohydrate-reduced nutrition in septic patients on ICU: study protocol for a prospective randomised controlled trial.

Authors:  Tim Rahmel; Max Hübner; Björn Koos; Alexander Wolf; Katrin-Maria Willemsen; Gabriele Strauß; David Effinger; Michael Adamzik; Simone Kreth
Journal:  BMJ Open       Date:  2020-07-08       Impact factor: 2.692

Review 5.  Phytochemicals as Novel Therapeutic Strategies for NLRP3 Inflammasome-Related Neurological, Metabolic, and Inflammatory Diseases.

Authors:  Carolina Pellegrini; Matteo Fornai; Luca Antonioli; Corrado Blandizzi; Vincenzo Calderone
Journal:  Int J Mol Sci       Date:  2019-06-13       Impact factor: 5.923

Review 6.  Uncovering the Role of p38 Family Members in Adipose Tissue Physiology.

Authors:  Magdalena Leiva; Nuria Matesanz; Marta Pulgarín-Alfaro; Ivana Nikolic; Guadalupe Sabio
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-23       Impact factor: 5.555

7.  Association of small intestinal bacterial overgrowth with nonalcoholic fatty liver disease in children: A meta-analysis.

Authors:  Linghan Kuang; Wei Zhou; Yongmei Jiang
Journal:  PLoS One       Date:  2021-12-02       Impact factor: 3.240

8.  Moderate SIRT1 overexpression protects against brown adipose tissue inflammation.

Authors:  Carmen Escalona-Garrido; Patricia Vázquez; Paula Mera; Sebastián Zagmutt; Ester García-Casarrubios; Ana Montero-Pedrazuela; Fernanda Rey-Stolle; Ana Guadaño-Ferraz; Francisco J Rupérez; Dolors Serra; Laura Herrero; Maria Jesus Obregon; Ángela M Valverde
Journal:  Mol Metab       Date:  2020-10-10       Impact factor: 7.422

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.